Prostate Cancer
Clinical research in metastatic castration-resistant prostate cancer focuses on therapy-refractory disease and PSMA-targeted immunotherapy approaches.
- PSMA-targeting bispecific γδ-T cell engagers
- Combination immunotherapy
- Metastatic castration-resistant prostate cancer
Interest extends to both measurable and non-measurable disease settings, with attention to antitumor activity and immune-based treatment strategies.
Acute Myeloid Leukemia
Research in relapsed/refractory acute myeloid leukemia centers on CD123-positive disease and targeted γδ-T cell engagement.
- CD123-positive AML
- Relapsed/refractory hematologic malignancy
- Bispecific immune cell engagement
The therapeutic focus includes patients with difficult-to-treat disease biology and an emphasis on immune-mediated anti-leukemic activity.
Myelodysplastic Syndromes
Clinical interest also includes myelodysplastic syndrome with intermediate-risk, high-risk, and extremely high-risk profiles.
- High-risk MDS
- Extremely high-risk MDS
- CD123-directed therapy
This area reflects a focus on advanced marrow disorders and targeted approaches for CD123-expressing disease.
Bispecific T-cell Engagers
Across its oncology portfolio, the sponsor is active in bispecific T-cell engager development using γδ-T cells and Vγ9Vδ2-T cell biology.
- γδ-T cell engager platforms
- CD123-targeting constructs
- PSMA-targeting constructs
The research landscape spans solid tumors and hematologic malignancies through antigen-directed immune activation.
